BiondVax Pharmaceuticals Ltd. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
33BiondVax Pharmaceuticals Ltd.'s Business Model
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
About BiondVax Pharmaceuticals Ltd.
Website: https://www.biondvax.com
CEO (Chief Executive Officer): Mr. Amir Reichman M.B.A., M.Sc.
IPO date: 2015-05-12
Contact
Country: IL
Address: Jerusalem BioPark Building
City: Jerusalem
State: None
Phone: 972 8 930 2529
Zip Code: None
Other
CIK: 0001611747
ISIN: US09073Q1058
CUSIP: 09073Q105
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
